Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 271

1.

[Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002].

Rieckmann P, Toyka KV; Multiple Sclerosis Therapy Consensus Group.

Nervenarzt. 2002 Jun;73(6):556-63. Review. German.

PMID:
12243005
2.

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker P, Gold R, Kallmann B, Leussink V, Mäurer M, Ruprecht K, Stoll G, Weilbach FX; Multiple Sclerosis Therapy Consensus Group.

J Neurol. 2004 Nov;251(11):1329-39. Review.

PMID:
15592728
3.

[A short history of beta-interferon therapy of multiple sclerosis].

Stock G, Horowski R.

Med Klin (Munich). 2001 Sep 15;96 Suppl 1:3-9. German.

PMID:
11603113
4.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
5.

[Immunomodulatory therapy in multiple sclerosis].

Csépány T, Bereczki D.

Ideggyogy Sz. 2004 Nov 20;57(11-12):401-16. Review. Hungarian.

PMID:
15662768
6.

The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.

Reggio E, Nicoletti A, Fiorilla T, Politi G, Reggio A, Patti F.

J Neurol. 2005 Oct;252(10):1255-61. Epub 2005 Jun 6.

PMID:
15940386
7.

[Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].

Multiple Sklerose-Therapie-Konsensus Gruppe (MSTKG).

Nervenarzt. 2001 Feb;72(2):150-7. Review. German.

PMID:
11256151
8.

[Choice of early and escalation treatment options for multiple sclerosis].

Linker RA, Kieseier BC.

Nervenarzt. 2008 Oct;79(10):1123-4,1126-8,1130-2 passim. doi: 10.1007/s00115-008-2521-3. Review. German.

PMID:
18806985
9.
10.

[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P.

Nervenarzt. 2006 Dec;77(12):1506-18. German.

PMID:
17136556
11.

[Beta-interferons in multiple sclerosis: comparative trials and potential individual selection in different types of the disease course].

Boĭko AN, Gusev EI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2002;Suppl:65-71. Review. Russian.

PMID:
12418395
12.
14.

Early-stage multiple sclerosis : what are the treatment options?

Soelberg Sorensen P.

Drugs. 2004;64(18):2021-9. Review.

PMID:
15341495
15.

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

Brown MG, Murray TJ, Sketris IS, Fisk JD, LeBlanc JC, Schwartz CE, Skedgel C.

Int J Technol Assess Health Care. 2000 Summer;16(3):751-67.

PMID:
11028131
16.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

17.

[The interferon beta therapy after the first clinical episode of demyelination in multiple sclerosis].

Demina TL, Khachanova NV, Davydovskaia MV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(3):15-9. Russian.

PMID:
16608106
18.

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.

Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V.

Neurol Sci. 2005 Dec;26 Suppl 4:S174-8.

PMID:
16388353
19.

Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Johnson KP, Due DL.

Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):205-14. doi: 10.1586/erp.09.20. Review.

PMID:
19527092
20.
Items per page

Supplemental Content

Write to the Help Desk